Crohn's disease is a recurrent inflammatory disorder of unknown aetiology and pathogenesis. Histologically, Crohn's disease is characterised by an important infiltration of proinflammatory cells involving the entire gastrointestinal tract from the mouth to the anus. The mechanisms underlying the inflammatory process are poorly understood. When infiltrated by inflammatory cells, the mucosa is known to generate a variety of inflammatory lipidic mediators' such as arachidonic acid metabolites -for example, prostaglandins, thromboxane, and leukotrienes -and platelet activating factor (also called platelet activating factor acether).
Platelet activating factor, first described in 1972 as platelet activating factor4 has been identified as 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine. Platelet activating factor is a lipid mediator derived from membrane phospholipids and involving in hypersensitivity and inflammatory reactions. It is synthetised by numerous human cell types, including neutrophils, monocytes, macrophages, platelets, eosinophils, vascular endothelial cells, and several cancer cell lines including gastric epithelial (HGT1) cells.6 1 It is capable of inducing inflammatory reactions such as increased vascular permeability, leucocyte adhesion and chemotaxis. Some of the manifestations of septic shock, such as hypotension, haemoconcentration, and gastrointestinal ulceration were reported to be mimicked after intravenous administration of platelet activating factor in rats suggesting that it plays a role in this syndrome.'"-" At present, little is known about the role of platelet activating factor in ulcerative diseases of the gastrointestinal tract in man, although it has been reported in mucosal biopsy specimens from patients with ulcerative colitis and Crohn's disease. '9 21 The aim of this study was to determine amounts of platelet activating factor and metabolites (lyso platelet activating factor and alkylacyl-glycerophosphocholine). In the intestinal mucosa of patients with Crohn's disease related to disease activity in order to assess the possible role of platelet activating factor in the pathogenesis of Crohn's disease.
Methods

SUBJECTS
Twenty six patients (12 men, 14 women; mean age 28 yr, ranging 30-80) with active Crohn's disease (duration of the disease one to 11 years) located to the colon (15), the ileum (three) or both (eight), were investigated. Their diagnoses were based on Morson's morphologic criteria and the activity of the disease was assessed on the Best index (CDAI) and biological parameters (erythrocyte sedimentation rate (ESR), white blood cell count (WBC), platelets, c globulin).
Ten healthy volunteers (five men, five women; mean age 31 yr, ranging PLATELET ACTIVATING FACTOR ASSAY Biopsy specimens were transferred into tubes with 80% ethanol as previously described for ethanolic platelet activating factor extraction from cells23 as well as from biopsies'9-2124 and frozen at -20°C until assayed for platelet activating factor activity. Twenty four hours before platelet activating factor assay, biopsy specimens in 80% ethanol were cut into small pieces (less than 1 mg). Extraction of platelet activating factor was performed during 10 hours at -4°C using a 'roller'. All samples were directly measured using the aggregation of washed rabbit platelets. Rabbit platelets were washed as described previously25: aspirinated platelets (1 6x 108) in 300 ,ul Tyrode's solution, containing 2.5% gelatin and the ADP scavenger mixture creatine phosphate (1 mM) and creatine phosphokinase (10 IU/ml) were stirred in an aggregometer (Icare, Marseille, France). The aggregating activity ofthe samples was measured over the linear portion of the calibration curve obtained with 5-50 pg of synthetic platelet activating factor.
ASSAY FOR LYSO PLATELET ACTIVATING FACTOR
Lyso platelet activating factor was chemically acetylated into platelet activating factor, extracted in ethanol and measured as previously described. 23 Briefly, the ethanolic extracts were dried under an air stream, mixed with 200 R1 pyridine and acetic anhydride and kept for 18 hours in the dark, at room temperature. The extracts were evaporated and traces of pyridine removed with dichloromethane. Samples recovered with 100 p.1 of 60% ethanol and then assayed as described above. The amount of lyso platelet activating factor was calculated as the difference between the quantity of platelet activating factor measured after and before acetylation of the samples.
Alkyl acyl glycerophosphocholine measured after alkaline hydrolysis and subsequent acetylation.23 Briefly, aliquots of the dried extracts were treated with 0.03 N NaOH in methanol for two hours at room temperature. The pH was adjusted to 7.0 with 1 N HC1 and the mixture was evaporated to dryness. The dried residues were then acetylated as described above and platelet activating factor was assayed. The amount of alkyl acyl glycerophosphocholine was calculated as the difference between the levels of platelet activating factor measured before and after alkaline hydrolysis and acetylation.
CHARACTERISATION OF PLATELET ACTIVATING FACTOR
For further characterisation of the platelet aggregation molecule, platelet activating factor extracted from biopsy specimens from patients with Crohn's disease was pooled, dried and eluted on high performance liquid chromatography.2'2426-28 The platelet aggregating activity was eluted from 18 to 21 minutes -that is, with a retention time similar to that of synthetic platelet activating factor. The efficiency of this procedure averaged 80% using [3H] platelet activating factor as internal standard. In addition to its ADP and aracachidonic acid independent aggregating activity on rabbit platelets, the lipidic material was further characterised as platelet activating factor on the basis of the following criteria: (a) its aggregating activity in the presence of 0. 1 mM BN 52021, a specific platelet activating factor receptor antagonist26; (b) its aggregating activity after incubation of the samples with 10 Rg/ml phospholipase A2 from hog pancreas and with 100 p.g/ml lipase A1 from R arrhizUs27; (c) its retention time during high performance liquid chromatography analysis using phosphatidylcholine, lysophosphatidylcholine, and synthetic C-18 platelet activating factor as standards.28
STATISTICAL ANALYSIS
All values are expressed as mean (standard error of the mean (SEM)). The Mann-Whitney U rank sum test and Spearman rank correlation test were used for statistical evaluation.
The study was approved by the Ethical Committee of the Bichat Hospital.
Results
CLINICAL AND BIOLOGICAL PARAMETERS
In acute Crohn's disease, the Best index (CDAI) was more than 150 in all patients with mean (SEM) 203 (23) . Biological parameters were consistent with systemic inflammation (m (SEM)): ESR=51 (5) mm/h, WBC= 10322 (632)/dl, platelets=439 (31) 103/del and a2 globulin= 8.4 (0.4) g/l. All these parameters were normal in patients with Crohn's disease in remission and in controls.
ENDOSCOPY
Endoscopy examination was normal in all the 10 were controls whereas ileal and/or colonic ulcerations and inflamed mucosa were noted in all Crohn's disease patients before prednisolone therapy. Flexible sigmoidoscopy showed occasional ulceration in the left colon in four of five patients examined during prednisolone therapy and normal mucosa in all patients with Crohn's Ulin4S eAc v11minUA ;in irLimicrifn HISTOPATHOLOGY None of the 10 controls had mucosal infiltration by inflammatory cells whereas in patients with active Crohn's disease, inflammatory cells were present in at least one site (left or right) of the colon (26) or in both (23) . Mucosal infiltration by inflammatory cells was ranged as absent, moderate, mild, intense in 3, 8, 9, 6 patients respectively in the right site of the colon and in 4, 6, 7, 8 patients respectively in the left site of the colon. After four weeks after prednisolone therapy (five) the inflammation decreased to a lesser extent: two with moderate mucosal inflammatory cell infiltration remained at moderate, two with mild musocal inflammatory cell infiltration returned to normal (absent) and one with intense mucosal inflammatory cell infiltration decreased to mild. The inflammatory cells were absent in the colonic mucosa of Crohn's disease patients examined in remission.
PLATELET ACTIVATING FACTOR IN COLONIC BIOPSIES
The platelet activating factor content of mucosal samples was significantly (p<001) higher in patients with Crohn's disease than in controls, both in the right (270 (100) v 25 (11) pg/mg net weight) and left colon (280 (110) v 30 (8) pg/ mgW) (Fig 1) .
Whatever the site of the biopsies, lyso platelet activating factor and alkyl acyl glycerophosphocholine concentrations were not significantly higher in Crohn's disease than in controls (4.5 
COMPARISON OF PLATELET ACTIVATING FACTOR CONCENTRATIONS WITH CLINICAL, BIOCHEMICAL, AND HISTOLOGICAL PARAMETERS
The mucosal content of platelet activating factor was higher (p<001) in inflamed than in noninflamed mucosa, but no significant correlation was observed with the severity of mucosal rNS inflammation (Fig 3) . Even the platelet activating factor levels were higher when mucosal histology examination showed granuloma (310 (70) pg/mgW) or mononuclear cells (300 (110) pg/mgW) than polymorphonuclear cells (170 (80) pg/mgW), there was no significant correlation between colonic platelet activating factor content and mucosal infiltration of different type of inflammatory cells (Fig 4) . (Fig 5) . There was no significant difference on mucosal content of platelet acti ing factor in patients with Crohn's diseas remission than in controls (p=0.07).
Discussion
The results obtained in this study indicate the mucosal platelet activating factor conter considerably increased in patients with a Crohn's disease, decreased by glucocorti( therapy and may return to normal concentrat in quiescent Crohn's disease. Platelet activa factor was extracted from biopsy specimens u ethanolic extraction as previously reported us24 and others.'9"20 Biopsy specimens shoulc conserved in 80% ethanol and frozen at -2 until assayed for platelet activating factor actir In these conditions, the platelet activating fa acetylhydrolase activity (the enzyme wl cleaves platelet activating factor into the inac lyso platelet activating factor) which is natui present in biopsy specimens is inactivated. 1 freeze treatment did not affect the acetylhy lase activity. Ethanolic extraction is now a c mon method of extracting platelet activa factor from various organs including bi( specimens. 1223224 In the present study the ag gating activity ofmaterials obtained from patii with Crohn's disease was characterised platelet activating factor according to: (i) its retention time from high performance liquid chromatography which was similar to that of synthetic platelet activating factor; (ii) its inhibition by specific platelet activating factor antagonist and phospholipase A2 (PLA2) and no by PLAl. [25] [26] [27] [28] The possibility that platelet activating factor may be involved in Crohn's disease has been suggested by Kald et al.20 These authors have shown that colonic platelet activating factor content was significantly increased irrespective of colonic inflammation. Our data supported by quantification of mucosal inflammatory cell infiltration, suggest that the increase of platelet activating factor levels in colonic mucosa of Crohn's disease patients are neither related to the severity nor the type of inflammatory cell infiltraFt *^tion. So far, the cellular origin of platelet activat-14)i ing factor from colonic mucosa remains unclear.
The lack of correlation between platelet activating factor content and the severity of inflammation in colonic mucosa shown by our present ivat findings, speaks against inflammatory cells as the i sole source of platelet activating factor synthesis.
We in In addition platelet activating factor was also acetyltransferase to yield a biologically active platelet activating factor molecule. 34 Eliakim et all9 have reported that prednisolone and 5-aminosalycilate inhibit colonic platelet activating factor synthesis in vitro. The mechanism of this inhibition is poorly understood. As PLA2 has been shown to be increased in Crohn's disease patients,3" 36 it has been postulated that steroids inhibit colonic platelet activating factor synthesis by interfering with PLA2 activity. The fact that lyso platelet activating factor concentrations are not significantly enhanced in acute Crohn's disease mucosa compared with normal mucosa, however, may suggest that raised platelet activating factor levels are related to an increased acetyltransferase rather than to PLA2 activity. The role of specific acetyltransferase activity in Crohn's disease patients has not been studied so far, and deserves investigation. It is unknown whether high activity of enzymes is related to change involving the inflammatory cells or both intestinal epithelial and inflammatory cells. Therefore we suggest that platelet activating factor should be considered as a global mucosal activity marker.
Because no significant difference was observed between colonic platelet activating factor content from the left or right sides of the colon and was unrelated to the extent of disease, biopsies from sigmoid may reflect the levels of platelet activating factor in the whole intestine.
In conclusion, the colonic platelet activating factor is raised in acute Crohn's disease patients irrespective of the severity or the type of inflammatory cell infiltration. As shown in this study, two biopsies from the left side of the colon are sufficient to assess the mucosal disease activity in Crohn's disease patients whatever the location of the disease. The role of platelet activating factor blocker in the treatment of inflammatory bowel disease deserves investigation.
